CN114129765B - Hemostatic material and preparation method and application thereof - Google Patents

Hemostatic material and preparation method and application thereof Download PDF

Info

Publication number
CN114129765B
CN114129765B CN202111435183.6A CN202111435183A CN114129765B CN 114129765 B CN114129765 B CN 114129765B CN 202111435183 A CN202111435183 A CN 202111435183A CN 114129765 B CN114129765 B CN 114129765B
Authority
CN
China
Prior art keywords
powder
parts
hemostatic material
wall
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202111435183.6A
Other languages
Chinese (zh)
Other versions
CN114129765A (en
Inventor
张君华
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202111435183.6A priority Critical patent/CN114129765B/en
Publication of CN114129765A publication Critical patent/CN114129765A/en
Application granted granted Critical
Publication of CN114129765B publication Critical patent/CN114129765B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0066—Medicaments; Biocides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/30—Compounds of undetermined constitution extracted from natural sources, e.g. Aloe Vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/418—Agents promoting blood coagulation, blood-clotting agents, embolising agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/04—Materials for stopping bleeding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of medical materials, and particularly relates to a hemostatic material, and a preparation method and application thereof. In the invention, the nano zeolite has regular pore channels and the capability of sieving powder and molecules, can block the exudation of white blood cells and red blood cells while rapidly absorbing water, accelerates the coagulation process and promotes the formation of blood crust; the wall-broken Ganoderma spore powder contains triterpene, has effects of stopping plasma and relieving pain, and can cooperate with nanometer zeolite to promote blood crust formation; the silicon dioxide powder has the properties of dispersion and water absorption, improves the viscosity resistance, caking resistance and moisture conductivity of the hemostatic material, and enhances the platelet aggregation speed and aggregation capacity; the fresh water pearl powder contains active ingredients of amino acid and taurine, and has the function of quickly stopping bleeding.

Description

Hemostatic material and preparation method and application thereof
Technical Field
The invention belongs to the technical field of medical materials, and particularly relates to a hemostatic material, and a preparation method and application thereof.
Background
The traditional wound bleeding hemostasis products comprise medical gauze, a tourniquet, a wound patch and a hemostasis bag, but the products have certain defects in the using process, for example, the medical gauze needs to apply larger compression force to the wound bleeding position when in use, and the hemostasis effect is poor; the wound plaster can not effectively coagulate blood and has poor hemostatic effect; the existing hemostatic bag is formed by attaching a packaging bag for coating hemostatic particles to the wound surface of a patient, which is easy to cause secondary skin injury (such as allergy and incapability of removing subsequent packaging after adhesion with the wound skin) of the patient.
In order to obtain a suitable hemostatic agent, several novel hemostatic technologies have been developed gradually in recent years, wherein, the hemostatic agent made of nano-grade material has attracted a lot of attention for clinical application due to its good hemostatic effect and flexible and diverse usage.
Chinese patent application CN101104080A discloses a zeolite hemostatic dressing prepared from 4A zeolite, a binder, lignin and optionally a molecular sieve activating powder, wherein the particle size of the zeolite hemostatic dressing is in the range of more than 0.2mm and less than 1mm, and the zeolite hemostatic dressing can physically and rapidly absorb water in blood, but cannot block the exudation of white blood cells with a diameter of 8-9 μm and red blood cells with a diameter of 6-8 μm, so that platelets and thrombin cannot be concentrated, the platelet aggregation speed and the platelet aggregation capability cannot be enhanced, and the hemostatic effect is poor.
Disclosure of Invention
In view of the above, an object of the present invention is to provide a hemostatic material that can rapidly absorb wound moisture, effectively prevent the exudation of white blood cells and red blood cells, and has an excellent hemostatic effect.
In order to achieve the purpose of the invention, the invention provides the following technical scheme:
the invention provides a hemostatic material which comprises the following components in parts by mass:
30-60 parts of nano zeolite, 20-40 parts of wall-broken ganoderma lucidum spore powder, 5-15 parts of silicon dioxide powder and 2-5 parts of fresh water pearl powder;
the pore diameter of the nano zeolite is 0.5-0.9 nm.
Preferably, the particle size of the nano zeolite is less than or equal to 200 nm.
Preferably, the wall-breaking rate of the wall-broken ganoderma lucidum spore powder is more than or equal to 95%.
Preferably, the median particle size of the silicon dioxide powder is less than or equal to 1 mu m; the particle size distribution is 0.4 to 2 μm.
Preferably, the median particle size of the fresh water pearl powder is less than or equal to 1 mu m; the particle size distribution is 0.6 to 3 μm.
The invention also provides a preparation method of the hemostatic material in the technical scheme, which comprises the following steps:
mixing nano zeolite, wall-broken ganoderma lucidum spore powder, silicon dioxide powder and fresh water pearl powder to obtain the hemostatic material.
The invention also provides application of the hemostatic material in the technical scheme in preparation of medical hemostatic products.
The invention provides a hemostatic material which comprises the following components in parts by mass: 30-60 parts of nano zeolite, 20-40 parts of wall-broken ganoderma lucidum spore powder, 5-15 parts of silicon dioxide powder and 2-5 parts of fresh water pearl powder; the pore diameter of the nano zeolite is 0.5-0.9 nm. In the invention, the nano zeolite has regular pore channels and the capability of sieving molecules, can block the exudation of white blood cells and red blood cells while rapidly absorbing water, accelerates the coagulation process and promotes the formation of blood crust; the wall-broken ganoderma lucidum spore powder contains triterpenes, has the functions of stopping plasma and relieving pain, can be used for promoting the formation of blood crusts by cooperating with the nano zeolite, has oiliness, can be combined with the nano zeolite, avoids the nano zeolite powder from being fluffy, and improves the hemostasis efficiency of the hemostasis material; the silicon dioxide powder has the properties of dispersion and water absorption, improves the viscosity resistance, caking resistance and moisture conductivity of the hemostatic material, and enhances the platelet aggregation speed and aggregation capacity; the fresh water pearl powder contains active ingredients of amino acid and taurine, and has the function of quickly stopping bleeding.
In addition, the wall-broken ganoderma lucidum spore powder also has the effects of diminishing inflammation and easing pain; the fresh water Margarita powder has anti-inflammatory effect, and is beneficial for the growth of wound cortex cells.
Experimental results show that the hemostatic material provided by the invention has an excellent hemostatic effect and is beneficial to rapid wound healing.
Detailed Description
The invention provides a hemostatic material which comprises the following components in parts by mass:
30-60 parts of nano zeolite, 20-40 parts of wall-broken ganoderma lucidum spore powder, 5-15 parts of silicon dioxide powder and 2-5 parts of fresh water pearl powder;
the pore diameter of the nano zeolite is 0.5-0.9 nm.
In the present invention, unless otherwise specified, the components are commercially available products well known to those skilled in the art.
In the invention, the hemostatic material comprises 30-60 parts by mass of nano zeolite, preferably 35-55 parts by mass, and more preferably 40-50 parts by mass. In the invention, the pore diameter of the nano zeolite is 0.5-0.9 nm. In the invention, the particle size of the nano zeolite is preferably less than or equal to 200nm, and more preferably 100-200 nm. In the invention, the purity of the nano zeolite is preferably more than or equal to 95%.
In the invention, the hemostatic material comprises, by mass, 20-40 parts of wall-broken ganoderma lucidum spore powder, preferably 22-38 parts, and more preferably 25-35 parts. In the invention, the wall-breaking rate of the wall-broken ganoderma lucidum spore powder is preferably not less than 95%, and more preferably 95-100%.
In the invention, the hemostatic material comprises 5-15 parts by mass of silicon dioxide powder, preferably 6-14 parts by mass, and more preferably 7-13 parts by mass. In the invention, the median particle size of the silicon dioxide powder is preferably less than or equal to 1 μm, and more preferably 0.6-0.9 μm; the particle size distribution is preferably 0.4 to 2 μm, more preferably 0.6 to 1.5. mu.m.
In the invention, the hemostatic material comprises 2-5 parts by mass of fresh water pearl powder, preferably 2.5-4.5 parts by mass, and more preferably 3-4 parts by mass. In the invention, the median particle size of the fresh water pearl powder is preferably less than or equal to 1 μm, and more preferably 0.7-0.9 μm; the particle size distribution is preferably 0.6 to 3 μm, more preferably 0.6 to 2 μm.
The invention also provides a preparation method of the hemostatic material in the technical scheme, which comprises the following steps:
mixing nano zeolite, wall-broken ganoderma lucidum spore powder, silicon dioxide powder and fresh water pearl powder to obtain the hemostatic material.
In the present invention, the nano zeolite is preferably commercially available or autonomously prepared. In the present invention, the nano zeolite is preferably obtained by pulverizing natural zeolite. In the present invention, the preparation method of the nano zeolite preferably includes: sequentially grinding natural zeolite by Raymond mill, grinding by nanometer sand mill, drying and grinding by airflow grinder. In the invention, the mesh number of the material obtained by grinding through the Raymond mill is preferably more than or equal to 300 meshes; the median particle size of the material obtained by crushing the nano sand mill is preferably less than or equal to 200 nm. In the invention, the drying temperature is preferably 95-120 ℃, and more preferably 100-115 ℃; the time is preferably 1 to 3 hours, and more preferably 1.5 to 2.5 hours.
In the present invention, the wall-broken ganoderma lucidum spore powder is preferably commercially available or prepared autonomously. In the present invention, when the wall-broken ganoderma lucidum spore powder is prepared autonomously, the preparation method of the wall-broken ganoderma lucidum spore powder preferably comprises: mixing Ganoderma spore powder and nanometer zeolite, and breaking cell wall to obtain the cell wall-broken Ganoderma spore powder. In the invention, the mass ratio of the ganoderma lucidum spore powder to the nano zeolite is preferably (2-4): (3-6), more preferably (2.5-3.5): (3.5-5.5). In the present invention, the method of the wall breaking treatment is preferably roller compaction, a frozen vibration mill or jet milling.
In the present invention, the silica powder is preferably purchased commercially or prepared autonomously. In the present invention, when the silica powder is prepared autonomously, the preparation method of the silica powder preferably includes: crushing the precipitated silicon dioxide to obtain silicon dioxide powder; the method of disruption is preferably jet milling. In the present invention, the apparatus for jet milling is preferably a jet mill, more preferably a flat jet mill.
In the present invention, the fresh water pearl powder is preferably commercially available or autonomously prepared. In the present invention, when the fresh water pearl powder is prepared autonomously, the preparation method of the fresh water pearl powder preferably includes: sequentially carrying out hammer type crushing and airflow crushing on the fresh water pearl to obtain the fresh water pearl powder. In the present invention, the hammer mill is preferably a hammer mill. In the invention, the mesh number of the material obtained by the hammer type grinding is preferably more than or equal to 80 meshes.
In the invention, the mixing of the nano zeolite, the wall-broken ganoderma lucidum spore powder, the silicon dioxide powder and the fresh water pearl powder is preferably airflow crushing mixing. In the present invention, the apparatus for jet milling and mixing is preferably a jet mill, more preferably a flat jet mill.
The invention also provides application of the hemostatic material in the technical scheme in preparation of medical hemostatic products.
The present invention is not particularly limited in its application, and may be applied using hemostatic articles well known to those skilled in the art.
In the present invention, the hemostatic material is preferably applied externally.
In order to further illustrate the present invention, the following examples are provided to describe the hemostatic materials of the present invention and the methods of preparation and use thereof in detail, but they should not be construed as limiting the scope of the present invention. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
The reagents used in the examples are all commercially available.
Example 1
According to the mass parts, 40 parts of nano zeolite with the particle size of less than or equal to 200nm and the pore diameter of 0.5-0.9 nm, 20 parts of wall-broken ganoderma lucidum spore powder with the wall-breaking rate of more than or equal to 95%, 10 parts of silicon dioxide powder with the median particle size of less than or equal to 1 μm and 2 parts of fresh water pearl powder with the median particle size of less than or equal to 1 μm are mixed by using an airflow pulverizer to obtain the hemostatic material.
Example 2
According to the mass parts, 60 parts of nano zeolite with the particle size of less than or equal to 200nm and the pore diameter of 0.5-0.9 nm, 20 parts of wall-broken ganoderma lucidum spore powder with the wall-breaking rate of more than or equal to 95%, 15 parts of silicon dioxide powder with the median particle size of less than or equal to 1 μm and 5 parts of fresh water pearl powder with the median particle size of less than or equal to 1 μm are mixed by using an airflow pulverizer to obtain the hemostatic material.
Example 3
According to the mass parts, 30 parts of nano zeolite with the particle size of less than or equal to 200nm and the pore diameter of 0.5-0.9 nm, 40 parts of wall-broken ganoderma lucidum spore powder with the wall-breaking rate of more than or equal to 95%, 5 parts of silicon dioxide powder with the median particle size of less than or equal to 1 mu m and 3 parts of fresh water pearl powder with the median particle size of less than or equal to 1 mu m are mixed by using an airflow pulverizer to obtain the hemostatic material.
Application example 1
For Liu ladies, people without stannum, aged 78 years, bedridden in 11 months fracture in 2018, suffering from hip bedsores, the hemostatic material prepared in the example 1 is applied to an affected part, the affected part does not bleed any more after 5 days and has heat sensation, and the bleeding is healed after 38 days instead of the example 3 on the sixth day;
the application dosage is as follows: 0.1 to 0.5g/cm 2 。
Application example 2
A Cai woman and a tin-free person are aged 85 years old and bedridden in 2018 months after fracture, the affected part is applied with the hemostatic material prepared in the example 2, the affected part does not bleed any more after 4 days and has burning sensation, and the affected part is healed after 42 days by using the example 3 instead on the sixth day;
the application dosage is as follows: 0.1 to 0.5g/cm 2 。
Application example 3
Wu Mr. Wu, Nanjing, 85 years old, bedridden, affected by hip bedsore in 1 month 2020, the hemostatic material prepared in example 3 was applied to the affected part, the affected part did not bleed any more after one week, and healed after 40 days; the patient suffers from the second bedsore on the back in 2 months in 2020, the hemostatic material prepared in example 3 is applied to the affected part, one of the two parts is healed for 30 days, and the other part is healed for 40 days;
the application dosage is as follows: 0.1 to 0.5g/cm 2 。
Comparative example 1
Mixing 15 parts of nano zeolite with the particle size of less than or equal to 200nm and the pore diameter of 0.5-0.9 nm, 30 parts of wall-broken ganoderma lucidum spore powder with the wall-breaking rate of more than or equal to 95%, 10 parts of silicon dioxide powder with the median particle size of less than or equal to 1 mu m and 5 parts of fresh water pearl powder with the median particle size of less than or equal to 1 mu m by using a jet mill to obtain the hemostatic material.
Comparative application example 1
Mr. Liu, Nanjing, 86 years old, bedridden in 2019 month 3, affected by hip bedsore, the hemostatic material prepared in the comparative example 1 is applied to the affected part, the affected part does not bleed any more after 10 days, and the affected part heals after 50 days.
The application dosage is as follows: the dosage is 0.1-0.5 g/cm 2 。
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.

Claims (7)

1. The hemostatic material is characterized by comprising the following components in parts by mass:
30-60 parts of nano zeolite, 20-40 parts of wall-broken ganoderma lucidum spore powder, 5-15 parts of silicon dioxide powder and 2-5 parts of fresh water pearl powder;
the aperture of the nano zeolite is 0.5-0.9 nm;
the nano zeolite is obtained by crushing natural zeolite.
2. Hemostatic material according to claim 1, wherein the nano zeolites have a particle size of 200nm or less.
3. The hemostatic material according to claim 1, wherein the wall-broken rate of the wall-broken ganoderma lucidum spore powder is not less than 95%.
4. Hemostatic material according to claim 1, wherein the silica powder has a median particle size of ≤ 1 μ ι η; the particle size distribution is 0.4 to 2 μm.
5. The hemostatic material of claim 1, wherein the median particle size of the fresh water pearl powder is less than or equal to 1 μm; the particle size distribution is 0.6 to 3 μm.
6. A method of preparing a haemostatic material according to any of claims 1 to 5, comprising the steps of:
mixing nano zeolite, wall-broken ganoderma lucidum spore powder, silicon dioxide powder and fresh water pearl powder to obtain the hemostatic material.
7. Use of a haemostatic material according to any of claims 1-5 in the manufacture of a medical haemostatic article.
CN202111435183.6A 2021-11-29 2021-11-29 Hemostatic material and preparation method and application thereof Active CN114129765B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111435183.6A CN114129765B (en) 2021-11-29 2021-11-29 Hemostatic material and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111435183.6A CN114129765B (en) 2021-11-29 2021-11-29 Hemostatic material and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN114129765A CN114129765A (en) 2022-03-04
CN114129765B true CN114129765B (en) 2022-08-16

Family

ID=80389577

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111435183.6A Active CN114129765B (en) 2021-11-29 2021-11-29 Hemostatic material and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN114129765B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101104080A (en) * 2007-04-24 2008-01-16 深圳市鸿华投资有限公司 Zeolite hemostatic dressings and preparation method and application thereof
CN106668925A (en) * 2016-12-23 2017-05-17 浙江大学常州工业技术研究院 Antibacterial hemostatic material as well as preparation method and use thereof
CN107007874A (en) * 2017-03-20 2017-08-04 江西虹景天药业有限公司 A kind of silicon substrate wound repair aqueous gel and preparation method thereof
CN111249518A (en) * 2018-12-01 2020-06-09 浙江大学 Hemostatic composition and preparation method thereof
CN113350448A (en) * 2021-06-25 2021-09-07 安徽利民生物科技股份有限公司 Ganoderma lucidum spore powder/clinopodium polycephalum composite hemostatic and anti-inflammatory powder and preparation method thereof
WO2021176457A1 (en) * 2020-03-05 2021-09-10 Ariel Scientific Innovations Ltd. Anti-hemorrhaging compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0526503D0 (en) * 2005-12-29 2006-02-08 Medtrade Products Ltd Hemostatic material

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101104080A (en) * 2007-04-24 2008-01-16 深圳市鸿华投资有限公司 Zeolite hemostatic dressings and preparation method and application thereof
CN106668925A (en) * 2016-12-23 2017-05-17 浙江大学常州工业技术研究院 Antibacterial hemostatic material as well as preparation method and use thereof
CN107007874A (en) * 2017-03-20 2017-08-04 江西虹景天药业有限公司 A kind of silicon substrate wound repair aqueous gel and preparation method thereof
CN111249518A (en) * 2018-12-01 2020-06-09 浙江大学 Hemostatic composition and preparation method thereof
WO2021176457A1 (en) * 2020-03-05 2021-09-10 Ariel Scientific Innovations Ltd. Anti-hemorrhaging compositions
CN113350448A (en) * 2021-06-25 2021-09-07 安徽利民生物科技股份有限公司 Ganoderma lucidum spore powder/clinopodium polycephalum composite hemostatic and anti-inflammatory powder and preparation method thereof

Also Published As

Publication number Publication date
CN114129765A (en) 2022-03-04

Similar Documents

Publication Publication Date Title
JP7061811B2 (en) Iron-containing oxide / nanokaolin composite hemostatic agent and its manufacturing method
CN101766551B (en) Drug toothpaste for treating oral diseases and preparation method thereof
WO2008034304A1 (en) Nanometer mesoporous silica-based xerogel styptic material and its preparing process and application
CN105999365B (en) A kind of effect type nose cavity hemostatic material and preparation method thereof
CN114306432B (en) Plant exosome composition with anti-hair loss and hair growth functions and preparation method thereof
CN106728744A (en) A kind of composition and its preparation of the promotion anti-scar of wound healing
CN104056301A (en) Traditional Chinese medicine-type hemostatic anti-inflammation liquid bandage and preparation method thereof
CN114748670A (en) Non-woven hemostatic gauze and preparation method and application thereof
CN114129765B (en) Hemostatic material and preparation method and application thereof
WO2018137319A1 (en) Application of sarcococca vagans, chinese medicinal ointment for treating skin disease, preparation method and application thereof
CN110917120A (en) Sticky antibacterial repairing material and preparation method and application thereof
CN109589444A (en) A kind of amenities comprising the antibacterial hypo-allergenic Chinese medicine composition of heat-clearing
CN104940627A (en) Traditional Chinese medicine composition for promoting wound healing, and preparation method of traditional Chinese medicine composition
CN103816247B (en) External medicine composition that trauma scarization heals and its preparation method can be prevented
CN1051236C (en) Styptic powder
CN115501385A (en) Wound film-forming dressing for promoting wound healing and preparation method thereof
CN112675354B (en) Multifunctional rhizoma bletillae medical material and preparation method and application thereof
CN112773816B (en) Wound repair spray and preparation method and application thereof
CN103536959B (en) Preparation method of postoperative pharmaceutical adjuvant paste for anorectal diseases
CN102940777A (en) Cough relieving and sore-throat relieving cataplasm and preparation method thereof
JPH02231426A (en) Drug preparation for skin application
CN112972368A (en) Pharmaceutical composition for promoting healing of postoperative wound surface of anorectal surgery and preparation method thereof
WO2019080115A1 (en) Long-acting sustained-release traditional chinese medicine cold compress for treating skin ulcer
CN105536028A (en) Dressing for promoting skin wound repair and preparing method
CN101670036A (en) External aloe vera dry jelly powder patch used for trauma wound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
PE01 Entry into force of the registration of the contract for pledge of patent right
PE01 Entry into force of the registration of the contract for pledge of patent right

Denomination of invention: A hemostatic material and its preparation method and application

Effective date of registration: 20230329

Granted publication date: 20220816

Pledgee: Bank of China Limited by Share Ltd. Xi'an North Main Street Branch

Pledgor: Zhang Junhua

Registration number: Y2023980036894